Evidence map›Paper›PMID 38487082›Full record

ArticleEXCLI journal2024

Immunoaffinity proteomics for kidney injury biomarkers in male beagle dogs.

Wael Naboulsi, Hannes Planatscher, Felix F Schmidt, Andreas Steinhilber, Thomas O Joos, Adeyemi O Adedeji, J Eric McDuffie, Oliver Poetz

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Wael NaboulsiSignatope GmbH, Reutlingen, Germany.
Hannes PlanatscherSignatope GmbH, Reutlingen, Germany.
Felix F SchmidtSignatope GmbH, Reutlingen, Germany.
Andreas SteinhilberSignatope GmbH, Reutlingen, Germany.
Thomas O JoosSignatope GmbH, Reutlingen, Germany.
Adeyemi O AdedejiDepartment of Safety Assessment, Genentech, A Member of the Roche Group, South San Francisco, CA, USA.
J Eric McDuffieJanssen Pharmaceutical Research & Development LLC, San Diego, California, USA.
Oliver PoetzSignatope GmbH, Reutlingen, Germany.
Signatope GmbH (Germany)Natural and Medical Sciences Institute · DENeurocrine Biosciences (United States) · USRoche (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced kidney injury (DIKI) is a cause of drug development failure. Dogs represent a common non-rodent animal model in pre-clinical safety studies; however, biomarker assays for detecting nephrotoxicity in dogs are limited. To identify novel proteins and gain insight into the molecular mechanisms involved in DIKI, we developed an assay to evaluate proteomic changes associated with DIKI in male beagle dogs that received nephrotoxic doses of tobramycin for 10 consecutive days. Label-free quantitative discovery proteomics analysis on representative kidney cortex tissues collected on Day 11 showed that the tobramycin-induced kidney injury led to a significant differential regulation of 94 proteins mostly associated with mechanisms of nephrotoxicity such as oxidative stress and proteasome degradation. For verification of the proteomic results, we developed a multiplex peptide-centric immunoaffinity liquid chromatography tandem mass spectrometry assay (IA LC-MS/MS) to evaluate the association of eight DIKI protein biomarker candidates using kidney cortices collected on Day 11 and urine samples collected on Days -4, 1, 3, 7 and 10. The results showed that most biomarkers evaluated were detected in the kidney cortices and their expression profile in tissue aligned with the label-free data. Cystatin C was the most consistent marker regardless of the magnitude of the renal injury while fatty acid-binding protein-4 (FABP4) and kidney injury molecule-1 (KIM-1) were the most affected biomarkers in response to moderate proximal tubular injury in absence of changes in serum-based concentrations of blood urea nitrogen or creatinine. In the urine, clusterin is considered the most consistent biomarker regardless of the magnitude and time of the renal injury. To our knowledge, this is the most comprehensive multiplex assay for the quantitative analysis of mechanism-based proximal tubular injury biomarkers in dogs.

Indexed as

biomarkersdrug-induced kidney injuryimmunoaffinity-LC-MSproteomics

Identifiers

PMID38487082
PMCPMC10938254
OpenAlexW4394758147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.